JP2010519260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519260A5 JP2010519260A5 JP2009550652A JP2009550652A JP2010519260A5 JP 2010519260 A5 JP2010519260 A5 JP 2010519260A5 JP 2009550652 A JP2009550652 A JP 2009550652A JP 2009550652 A JP2009550652 A JP 2009550652A JP 2010519260 A5 JP2010519260 A5 JP 2010519260A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- pharmaceutical composition
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000969 carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 2
- 101150109738 Ptger4 gene Proteins 0.000 claims 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 2
- 229960002986 dinoprostone Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90349407P | 2007-02-26 | 2007-02-26 | |
| US60/903,494 | 2007-02-26 | ||
| PCT/CA2008/000351 WO2008104055A1 (en) | 2007-02-26 | 2008-02-22 | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010519260A JP2010519260A (ja) | 2010-06-03 |
| JP2010519260A5 true JP2010519260A5 (OSRAM) | 2011-03-31 |
| JP5301469B2 JP5301469B2 (ja) | 2013-09-25 |
Family
ID=39720805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009550652A Expired - Fee Related JP5301469B2 (ja) | 2007-02-26 | 2008-02-22 | Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8158671B2 (OSRAM) |
| EP (1) | EP2114877B1 (OSRAM) |
| JP (1) | JP5301469B2 (OSRAM) |
| CN (1) | CN101622230B (OSRAM) |
| AU (1) | AU2008221194B2 (OSRAM) |
| CA (1) | CA2679175C (OSRAM) |
| ES (1) | ES2400293T3 (OSRAM) |
| WO (1) | WO2008104055A1 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008136382A1 (ja) | 2007-04-26 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 二環性化合物およびその医薬用途 |
| JP5375824B2 (ja) | 2008-05-14 | 2013-12-25 | アステラス製薬株式会社 | アミド化合物 |
| CN102149384B (zh) * | 2008-08-14 | 2014-08-20 | 南京奥昭生物科技有限公司 | 作为ep4受体拮抗剂的杂环酰胺衍生物 |
| US20110287112A1 (en) | 2009-01-30 | 2011-11-24 | Ono Pharmaceutical Co., Ltd. | Prostate cancer progression inhibitor and progression inhibition method |
| WO2010121382A1 (en) * | 2009-04-21 | 2010-10-28 | Merck Frosst Canada Ltd. | Process for making indole cyclopropyl amide derivatives |
| BR112012028556A2 (pt) * | 2010-05-07 | 2014-04-01 | Glaxosmithkline Llc | Indóis |
| SI2619182T1 (sl) | 2010-09-21 | 2017-03-31 | Eisai R&D Management Co., Ltd. | Farmacevtski sestavek |
| US8828987B2 (en) | 2010-12-10 | 2014-09-09 | Rottapharm Biotech S.R.L. | Pyridine amide derivatives as EP4 receptor antagonists |
| ES2564353T3 (es) | 2011-07-04 | 2016-03-22 | Rottapharm Biotech S.R.L. | Derivados de aminas cíclicas como agonistas de los receptores EP4 |
| CA2839116C (en) | 2011-07-04 | 2019-07-16 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor antagonists |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| US9295665B2 (en) | 2013-03-12 | 2016-03-29 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors |
| NO3009426T3 (OSRAM) * | 2013-06-12 | 2018-09-29 | ||
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| KR102684436B1 (ko) | 2015-10-16 | 2024-07-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Ep4 길항제 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN109475520B (zh) * | 2016-07-07 | 2021-05-14 | 小野药品工业株式会社 | 包含ep4拮抗剂和免疫检查点抑制剂的组合 |
| WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
| US11066405B2 (en) * | 2017-04-18 | 2021-07-20 | Tempest Therapeutics, Inc. | Bicyclic compounds and their use in the treatment of cancer |
| JP7264060B2 (ja) | 2017-04-18 | 2023-04-25 | テンペスト セラピューティクス，インク． | 二環式化合物および癌の処置におけるそれらの使用 |
| US11325899B2 (en) | 2017-05-18 | 2022-05-10 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators |
| HUE056382T2 (hu) | 2017-05-18 | 2022-02-28 | Idorsia Pharmaceuticals Ltd | Pirimidin-származékok mint PGE2 receptor modulátorok |
| AR111806A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos |
| AU2018269666B2 (en) | 2017-05-18 | 2022-02-03 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| JP7253500B2 (ja) | 2017-05-18 | 2023-04-06 | イドーシア ファーマシューティカルズ リミテッド | ピリミジン誘導体 |
| WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
| EP3759114A4 (en) * | 2018-03-02 | 2021-12-15 | Shenzhen Ionova Life Science Co., Ltd. | HETEROBICYCLIC CARBOXYLIC ACIDS AND THEIR SALTS |
| DK3781550T3 (da) | 2018-04-17 | 2025-01-27 | Tempest Therapeutics Inc | Bicykliske carboxamider og fremgangsmåder til anvendelse deraf |
| JP2021524494A (ja) * | 2018-07-12 | 2021-09-13 | ロッタファーム・バイオテック・エッセ・エッレ・エッレ | Ｅｐ４受容体アンタゴニストとしての（ｒ）−４−（１−（１−（４−（トリフルオロメチル）ベンジル）ピロジリン−２−カルボキサミド）シクロプロピル）安息香酸 |
| CN111989311B (zh) * | 2019-01-22 | 2022-03-22 | 凯复(苏州)生物医药有限公司 | 抑制pge2/ep4信号传导的化合物、其制备方法及其在医药上的应用 |
| EP3722319A1 (en) | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| EP3827828A1 (en) | 2019-11-29 | 2021-06-02 | Rottapharm Biotech S.r.l. | (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification |
| WO2021115560A1 (en) | 2019-12-09 | 2021-06-17 | Rottapharm Biotech S.R.L. | New fyn and vegfr2 kinase inhibitors |
| EP3885339A1 (en) | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Process for the preparation of (r)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
| WO2022247881A1 (zh) * | 2021-05-28 | 2022-12-01 | 凯复(苏州)生物医药有限公司 | 治疗肿瘤的联合疗法 |
| CN115448913A (zh) * | 2021-06-08 | 2022-12-09 | 武汉人福创新药物研发中心有限公司 | 用于治疗ep2、ep4受体介导的疾病的双环化合物 |
| CA3230102A1 (en) * | 2021-08-27 | 2023-03-02 | Yongqi Deng | Solid form of indole compound, preparation method therefor and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2259998C2 (ru) * | 2000-03-09 | 2005-09-10 | Оно Фармасьютикал Ко., Лтд. | Производные индола, способ их получения и их применение |
| EP1267867B1 (en) * | 2000-03-24 | 2008-05-14 | Asterand Uk Limited | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| AU7705601A (en) * | 2000-07-25 | 2002-02-05 | Merck & Co Inc | N-substituted indoles useful in the treatment of diabetes |
| BRPI0414130B8 (pt) * | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
| JP5289046B2 (ja) * | 2005-05-19 | 2013-09-11 | メルク カナダ インコーポレイテッド | Ｅｐ４アンタゴニストとしてのキノリン誘導体 |
| CA2648729A1 (en) * | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Indole amide derivatives as ep4 receptor antagonists |
| US7705035B2 (en) * | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
-
2008
- 2008-02-22 CN CN2008800061949A patent/CN101622230B/zh not_active Expired - Fee Related
- 2008-02-22 AU AU2008221194A patent/AU2008221194B2/en not_active Ceased
- 2008-02-22 CA CA2679175A patent/CA2679175C/en not_active Expired - Fee Related
- 2008-02-22 US US12/527,736 patent/US8158671B2/en active Active
- 2008-02-22 JP JP2009550652A patent/JP5301469B2/ja not_active Expired - Fee Related
- 2008-02-22 ES ES08714673T patent/ES2400293T3/es active Active
- 2008-02-22 WO PCT/CA2008/000351 patent/WO2008104055A1/en not_active Ceased
- 2008-02-22 EP EP08714673A patent/EP2114877B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519260A5 (OSRAM) | ||
| JP2009530398A5 (OSRAM) | ||
| JP2017513836A5 (OSRAM) | ||
| RU2017117413A (ru) | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона | |
| JP2010077141A5 (OSRAM) | ||
| JP2007302689A5 (OSRAM) | ||
| JP2009536191A5 (OSRAM) | ||
| JP2013518107A5 (OSRAM) | ||
| JP2010502730A5 (OSRAM) | ||
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| JP2010525056A5 (OSRAM) | ||
| JP2013519632A5 (OSRAM) | ||
| JP2011500659A5 (OSRAM) | ||
| JP2010265321A5 (OSRAM) | ||
| JP2012533546A5 (OSRAM) | ||
| JP2011527332A5 (OSRAM) | ||
| JP2016511753A5 (OSRAM) | ||
| JP2008533007A5 (OSRAM) | ||
| JP2017529389A5 (OSRAM) | ||
| JP2011088926A5 (OSRAM) | ||
| JP2011246469A5 (OSRAM) | ||
| JP2015509075A5 (OSRAM) | ||
| JP2013525356A5 (OSRAM) | ||
| NZ603108A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| NZ596820A (en) | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |